Home Featured Page 23

Featured

Latest

Toad, Truth, and the Trouble with 5-MeO: Why Bufo alvarius Needs Our Protection

One Year After FDA’s MDMA Rejection: Insiders and Observers Reflect

From Huxley to Heffter: Mark Geyer Reflects on a Life in Psychedelic Research

Advanced Shadow Work and Psychedelic Integration: A Jungian Path to Wholeness

Pα+ Psychedelic Bulletin #177: Bright Minds Surges on Longboard’s Seizure Drug...

How Shadow Work Can Be a Powerful Tool for Psychedelic Transformation

The FDA, MDMA, and Public Perception: Was the FDA Fair to...

Pα+ Psychedelic Bulletin #176: Drug Developers Discuss Trial Design; Massachusetts Vote...

Protecting Indigenous Wisdom: Rethinking Psychedelic Legalization

Massachusetts Psychiatrists Push Back on Psychedelic Reform as Ballot Vote Looms:...

The Science Behind How Psychedelics Inspire Creative Breakthroughs

Psychedelic Funding Update: Q3 2024

The Hero’s Journey: Finding Your Story in Psychedelic Healing

Illuminating the Hidden Self: Navigating the Jungian Shadow with Psychedelics

1...222324...295 Page 23 of 295

Toad, Truth, and the Trouble with 5-MeO: Why Bufo alvarius Needs...

One Year After FDA’s MDMA Rejection: Insiders and Observers Reflect

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Toad, Truth, and the Trouble with 5-MeO: Why Bufo alvarius Needs Our Protection

One Year After FDA’s MDMA Rejection: Insiders and Observers Reflect

Harry Pack NFT – Last Call

From Huxley to Heffter: Mark Geyer Reflects on a Life in Psychedelic Research

Advanced Shadow Work and Psychedelic Integration: A Jungian Path to Wholeness

Pα+ Psychedelic Bulletin #177: Bright Minds Surges on Longboard’s Seizure Drug...

How Shadow Work Can Be a Powerful Tool for Psychedelic Transformation

The FDA, MDMA, and Public Perception: Was the FDA Fair to...

Pα+ Psychedelic Bulletin #176: Drug Developers Discuss Trial Design; Massachusetts Vote...

Protecting Indigenous Wisdom: Rethinking Psychedelic Legalization

Massachusetts Psychiatrists Push Back on Psychedelic Reform as Ballot Vote Looms:...

The Science Behind How Psychedelics Inspire Creative Breakthroughs

Psychedelic Funding Update: Q3 2024

The Hero’s Journey: Finding Your Story in Psychedelic Healing

Illuminating the Hidden Self: Navigating the Jungian Shadow with Psychedelics

EDITOR PICKS

Toad, Truth, and the Trouble with 5-MeO: Why Bufo alvarius Needs...

One Year After FDA’s MDMA Rejection: Insiders and Observers Reflect

Harry Pack NFT – Last Call

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY